Bristol-Myers Squibb Stock News

If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Opdivo plus Yervoy as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced HCC.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.

I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with a...

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Presents Results from CheckMate -8HW.

This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to exceed $190 billion by 2028. Every year, regulatory agencies approve dozens of biosimilars and brand-name drugs, so Seeking Alpha readers should be careful when making decisions.

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in sales across different uses.  Company executives said each treatment type they are studying has multibillion dollar potential, including Alzheimer's disease psychosis, agitation and cognition, along...